The AI in oncology market is entering a rapid expansion phase as healthcare providers, researchers, and pharmaceutical companies increasingly use artificial intelligence to improve cancer diagnostics, treatment planning, and research. The market was valued at USD 6.0 billion in 2025 and is projected to grow from USD 8.3 billion in 2026 to USD 38.9 billion by 2033, registering a CAGR of 24.8% from 2026 to 2033. North America held the largest regional share at 45.8% in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.

Download a free sample copy of the AI In Oncology market report to understand detailed coverage and inclusions in the final report

Core Drivers Accelerating Adoption

Soaring Cancer Incidence

The increasing prevalence of cancer is creating a stronger need for advanced diagnostic and treatment technologies. AI can analyze large volumes of medical information and assist healthcare professionals in identifying patterns associated with cancer detection, classification, and treatment management. The growing need for early detection is therefore supporting the integration of AI across oncology workflows.

AI-powered systems can process information from imaging technologies such as MRI, CT, PET, and ultrasound. These capabilities can assist with routine tasks including segmentation, quantification, and pattern recognition, allowing clinicians to focus on more complex diagnostic and treatment decisions.

The Rise of Multi-Omics Data

The increasing availability of complex biological and clinical datasets is creating opportunities for AI to support precision oncology. AI technologies can analyze multi-omics and real-world data to identify patterns that may be difficult to detect through conventional approaches.

This capability is particularly relevant to personalized treatment strategies. AI-based tools can help researchers and clinicians evaluate individual characteristics and treatment responses, supporting more targeted approaches to cancer management. The growing adoption of precision medicine is consequently strengthening demand for AI technologies within oncology.

Pharma R&D Rallies for Efficiency

Pharmaceutical and biotechnology companies are increasingly applying AI to cancer drug discovery, target identification, clinical research, and treatment development. AI and machine learning can analyze extensive datasets, streamline research workflows, and support the identification of potential therapeutic opportunities.

The research and development application is expected to register the fastest CAGR during the forecast period. Growing investments from pharmaceutical and biotechnology companies, together with advances in machine learning and deep learning, are helping expand AI applications throughout oncology research.

Segment Breakdown

Hardware led the component segment with a revenue share of 39.4% in 2025, supported by the increasing use of AI-enabled medical devices. However, software solutions are expected to grow at the fastest rate from 2026 to 2033 as healthcare providers and payers increasingly adopt AI platforms for oncology applications.
Breast cancer represented the largest cancer type segment, accounting for 20.9% of revenue in 2025. The prostate cancer segment is expected to register the fastest CAGR during the forecast period as AI-based tools continue to support detection, classification, and treatment-related workflows.
Diagnostics dominated the application segment with a 37% revenue share in 2025. AI is increasingly being incorporated into cancer screening, imaging analysis, pathology, and early detection processes. Hospitals led the end-use segment with a 48% share in 2025 as healthcare institutions increasingly integrate AI into diagnostic and treatment environments.

Regional Insights

North America dominated the AI in oncology market with a 45.8% revenue share in 2025. Developed digital infrastructure, favorable regulatory and reimbursement policies, government initiatives, and increasing cancer prevalence are supporting adoption across the region. The U.S. held the largest country-level revenue share in 2025.
Asia Pacific is expected to experience the fastest growth from 2026 to 2033. Increasing digitalization in hospitals and diagnostic laboratories, rising cancer prevalence, and growing adoption of AI technologies are creating strong opportunities. China held the largest share within the Asia Pacific market in 2025.
Europe is also progressing as healthcare organizations pursue value-based care and increase investments in artificial intelligence. Latin America is benefiting from collaborations between technology companies and healthcare providers, while the Middle East and Africa are gaining opportunities through digital healthcare initiatives and increasing awareness of AI-supported oncology solutions.

FAQ’s

What is driving AI in oncology market growth?

Rising cancer prevalence, increasing demand for early detection, precision medicine, AI-powered diagnostics, and growing pharmaceutical R&D investments are driving market growth.

Which segment leads the AI in oncology market?

The hardware segment leads by component with a 39.4% revenue share in 2025, while diagnostics leads by application with a 37% share.

Key AI In Oncology Companies:

Azra AI
ICAD, INC.
Siemens Healthcare GmbH
Intel Corporation

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Explore our dedicated business services:

Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:

Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

From Imaging to Drug Discovery, AI Is Transforming Oncology Workflows

The global AI in oncology market size was valued at USD 6.0 billion in 2025 and is projected to grow from USD 8.3 billion in 2026 to USD 38.9 billion by 2033